Reprogramming the tumor microenvironment to enhance adoptive cellular therapy

Seminars in Immunology

Volumn 28, Issue 1, 2016, Pages 64-72

  Beavis, Paul A ^a,b   Slaney, Clare Y ^a,b   Kershaw, Michael H ^a,b,c   Gyorki, David ^a,b   Neeson, Paul J ^a,b   Darcy, Phillip K ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Adoptive cellular therapy; Cancer; Chimeric antigen receptor; Immunosuppression; Immunotherapy

Indexed keywords

CANCER TESTIS ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLT3 LIGAND; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 25; INTERLEUKIN 6; IPILIMUMAB; MELAN A; MITOGEN ACTIVATED PROTEIN KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; CANCER VACCINE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE SYNDROME; GENETIC ENGINEERING; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; MELANOMA; METASTATIC MELANOMA; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL SURVIVAL; COMBINED MODALITY THERAPY; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84947561076     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.11.003     Document Type: Review

References (185)

1. Maus M.V., Grupp S.A., Porter D.L., June C.H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014, 123:2625-2635.
2. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
3. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
4. Melero I., Rouzaut A., Motz G.T., Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014, 4:522-526.
5. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
6. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.
7. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4275-4280.
8. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207:2187-2194.
9. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210:1695-1710.
10. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 2009, 206:1717-1725.
11. Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20:5064-5074.
12. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014, 32:1020-1030.
13. Wolchok J.D., Hodi F.S., Weber J.S., Allison J.P., Urba W.J., Robert C., et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann. N. Y. Acad. Sci. 2013, 1291:1-13.
14. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
15. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
16. Twyman-Saint Victor C., Rech A.J., Maity A., Rengan R., Pauken K.E., Stelekati E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377.
17. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372:320-330.
18. Peng W., Liu C., Xu C., Lou Y., Chen J., Yang Y., et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 2012, 72:5209-5218.
19. Blake S.J., Ching A.L., Kenna T.J., Galea R., Large J., Yagita H., et al. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. PLOS ONE 2015, 10:e0119483.
20. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
21. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer 2010, 127:759-767.
22. Diaz-Montero C.M., Finke J., Montero A.J. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin. Oncol. 2014, 41:174-184.
23. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
24. Ruffell B., Coussens L.M. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015, 27:462-472.
25. Marsafy S.E., Larghero J. Mesenchymal stem cells: key actors in tumor niche. Curr. Stem Cell Res. Ther. 2015, 10:523-529.
26. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
27. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
28. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006, 66:5716-5722.
29. Chun E., Lavoie S., Michaud M., Gallini C.A., Kim J., Soucy G., et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 2015, 12:244-257.
30. Ladoire S., Martin F., Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol. Immunother. 2011, 60:909-918.
31. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
32. Broz M.L., Binnewies M., Boldajipour B., Nelson A.E., Pollack J.L., Erle D.J., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014, 26:638-652.
33. Ruffell B., Chang-Strachan D., Chan V., Rosenbusch A., Ho C.M., Pryer N., et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014, 26:623-637.
34. Figlin R.A., Pierce W.C., Kaboo R., Tso C.L., Moldawer N., Gitlitz B., et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J. Urol. 1997, 158:740-745.
35. Quattrocchi K.B., Miller C.H., Cush S., Bernard S.A., Dull S.T., Smith M., et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol. 1999, 45:141-157.
36. Zhou J., Shen X., Huang J., Hodes R.J., Rosenberg S.A., Robbins P.F. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 2005, 175:7046-7052.
37. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
38. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:720-724.
39. Finney H.M., Lawson A.D., Bebbington C.R., Weir A.N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 1998, 161:2791-2797.
40. Carpenito C., Milone M.C., Hassan R., Simonet J.C., Lakhal M., Suhoski M.M., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3360-3365.
41. Zhong X.S., Matsushita M., Plotkin J., Riviere I., Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 2010, 18:413-420.
42. Tammana S., Huang X., Wong M., Milone M.C., Ma L., Levine B.L., et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther. 2010, 21:75-86.
43. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368:1509-1518.
44. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 2013, 5. 177ra138.
45. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
46. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014, 371:1507-1517.
47. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
48. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3. 95ra73.
49. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
50. Wang Y., Zhang W.Y., Han Q.W., Liu Y., Dai H.R., Guo Y.L., et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin. Immunol. 2014, 155:160-175.
51. Kershaw M.H., Westwood J.A., Darcy P.K. Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 2013, 13:525-541.
52. Klages K., Mayer C.T., Lahl K., Loddenkemper C., Teng M.W., Ngiow S.F., et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010, 70:7788-7799.
53. Li X., Kostareli E., Suffner J., Garbi N., Hammerling G.J. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur. J. Immunol. 2010, 40:3325-3335.
54. Cotechini T., Medler T.R., Coussens L.M. Myeloid cells as targets for therapy in solid tumors. Cancer J. 2015, 21:343-350.
55. Wallen H., Thompson J.A., Reilly J.Z., Rodmyre R.M., Cao J., Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS ONE 2009, 4:e4749.
56. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
57. Formenti S.C., Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst. 2013, 105:256-265.
58. Seyedin S.N., Schoenhals J.E., Lee D.A., Cortez M.A., Wang X., Niknam S., et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 2015, (Epub ahead of print).
59. Beavis P.A., Slaney C.Y., Kershaw M.H., Neeson P.J., Darcy P.K. Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy 2015, 7:499-512.
60. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
61. Ma Y., Adjemian S., Mattarollo S.R., Yamazaki T., Aymeric L., Yang H., et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38:729-741.
62. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013, 31:51-72.
63. Vacchelli E., Senovilla L., Eggermont A., Fridman W.H., Galon J., Zitvogel L., et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013, 2:e23510.
64. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
65. Ercolini A.M., Ladle B.H., Manning E.A., Pfannenstiel L.W., Armstrong T.D., Machiels J.P., et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 2005, 201:1591-1602.
66. Lutsiak M.E., Semnani R.T., De Pascalis R., Kashmiri S.V., Schlom J., Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868.
67. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34:336-344.
68. Zhu Y., Liu N., Xiong S.D., Zheng Y.J., Chu Y.W. CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. Scand. J. Immunol. 2011, 73:301-308.
69. Zhang L., Dermawan K., Jin M., Liu R., Zheng H., Xu L., et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin. Immunol. 2008, 129:219-229.
70. Ko H.J., Kim Y.J., Kim Y.S., Chang W.S., Ko S.Y., Chang S.Y., et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007, 67:7477-7486.
71. Fridlender Z.G., Sun J., Singhal S., Kapoor V., Cheng G., Suzuki E., et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol. Ther. 2010, 18:1947-1959.
72. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
73. Ding Z.C., Lu X., Yu M., Lemos H., Huang L., Chandler P., et al. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res. 2014, 74:3441-3453.
74. Alizadeh D., Trad M., Hanke N.T., Larmonier C.B., Janikashvili N., Bonnotte B., et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014, 74:104-118.
75. Mikyskova R., Indrova M., Vlkova V., Bieblova J., Simova J., Parackova Z., et al. DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J. Leukoc. Biol. 2014, (Epub ahead of print).
76. Umansky V., Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol. Immunother. 2012, 61:275-282.
77. Kodumudi K.N., Weber A., Sarnaik A.A., Pilon-Thomas S. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J. Immunol. 2012, 189:5147-5154.
78. Ugel S., Peranzoni E., Desantis G., Chioda M., Walter S., Weinschenk T., et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2012, 2:628-639.
79. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982, 155:1063-1074.
80. Medina-Echeverz J., Fioravanti J., Zabala M., Ardaiz N., Prieto J., Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J. Immunol. 2011, 186:807-815.
81. Medina-Echeverz J., Berraondo P. Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells. Oncoimmunology 2012, 1:118-120.
82. Bracci L., Moschella F., Sestili P., La Sorsa V., Valentini M., Canini I., et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 2007, 13:644-653.
83. Xu W., Cai J., Li S., Zhang H., Han J., Wen M., et al. Improving the in vivo persistence, distribution and function of cytotoxic T lymphocytes by inhibiting the tumor immunosuppressive microenvironment. Scand. J. Immunol. 2013, 78:50-60.
84. Zhou Q., Bucher C., Munger M.E., Highfill S.L., Tolar J., Munn D.H., et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 2009, 114:3793-3802.
85. Baba J., Watanabe S., Saida Y., Tanaka T., Miyabayashi T., Koshio J., et al. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 2012, 120:2417-2427.
86. Mok S., Koya R.C., Tsui C., Xu J., Robert L., Wu L., et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014, 74:153-161.
87. Lesokhin A.M., Hohl T.M., Kitano S., Cortez C., Hirschhorn-Cymerman D., Avogadri F., et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2012, 72:876-886.
88. Highfill S.L., Long A.H., Orentas R.J., Mackall C.L. Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors. J. Immunother. Cancer 2013, 1:p265.
89. Nagaraj S., Youn J.I., Weber H., Iclozan C., Lu L., Cotter M.J., et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res. 2010, 16:1812-1823.
90. Ninomiya S., Narala N., Huye L., Yagyu S., Savoldo B., Dotti G., et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 2015, 125:3905-3916.
91. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
92. Beatty G.L., Torigian D.A., Chiorean E.G., Saboury B., Brothers A., Alavi A., et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2013, 19:6286-6295.
93. Curran K.J., Seinstra B.A., Nikhamin Y., Yeh R., Usachenko Y., van Leeuwen D.G., et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol. Ther. 2015, 23:769-778.
94. Abate-Daga D., Hanada K., Davis J.L., Yang J.C., Rosenberg S.A., Morgan R.A. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood 2013, 122:1399-1410.
95. Moon E.K., Wang L.C., Dolfi D.V., Wilson C.B., Ranganathan R., Sun J., et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin. Cancer Res. 2014, 20:4262-4273.
96. John L.B., Devaud C., Duong C.P., Yong C.S., Beavis P.A., Haynes N.M., et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 2013, 19:5636-5646.
97. Moon E.K., Ranganathan R., Eruslanov E., Kim S., Newick K., O'Brien S., et al. Blockade of programmed death 1 augments the ability of human T cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer. Clin. Cancer Res. 2015, (Epub ahead of print).
98. Berrien-Elliott M.M., Jackson S.R., Meyer J.M., Rouskey C.J., Nguyen T.L., Yagita H., et al. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res. 2013, 73:605-616.
99. Mahvi D.A., Meyers J.V., Tatar A.J., Contreras A., Suresh M., Leverson G.E., et al. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice. J. Immunother. 2015, 38:54-61.
100. Anderson A.C. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2014, 2:393-398.
101. Huang Y.H., Zhu C., Kondo Y., Anderson A.C., Gandhi A., Russell A., et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015, 517:386-390.
102. Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., Sander C., et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012, 72:887-896.
103. Wang L., Kang F.B., Shan B.E. B7-H3-mediated tumor immunology: friend or foe?. Int. J. Cancer 2014, 134:2764-2771.
104. Dangaj D., Lanitis E., Zhao A., Joshi S., Cheng Y., Sandaltzopoulos R., et al. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res. 2013, 73:4820-4829.
105. Leung J., Suh W.K. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model. J. Immunol. 2013, 190:6651-6661.
106. Lines J.L., Pantazi E., Mak J., Sempere L.F., Wang L., O'Connell S., et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014, 74:1924-1932.
107. Shin J.H., Park H.B., Oh Y.M., Lim D.P., Lee J.E., Seo H.H., et al. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood 2012, 119:5678-5687.
108. Ankri C., Shamalov K., Horovitz-Fried M., Mauer S., Cohen C.J. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. J. Immunol. 2013, 191:4121-4129.
109. Kobold S., Grassmann S., Chaloupka M., Lampert C., Wenk S., Kraus F., et al. Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J. Natl. Cancer Inst. 2015, 107.
110. Borkner L., Kaiser A., van de Kasteele W., Andreesen R., Mackensen A., Haanen J.B., et al. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol. Immunother. 2010, 59:1173-1183.
111. Teo P.Y., Yang C., Whilding L.M., Parente-Pereira A.C., Maher J., George A.J., et al. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing. Adv. Healthc. Mater. 2015, 4:1180-1189.
112. Ohta A., Gorelik E., Prasad S.J., Ronchese F., Lukashev D., Wong M.K., et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13132-13137.
113. Beavis P.A., Stagg J., Darcy P.K., Smyth M.J. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 2012, 33:231-237.
114. Hatfield S.M., Kjaergaard J., Lukashev D., Belikoff B., Schreiber T.H., Sethumadhavan S., et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1alpha-dependent and extracellular adenosine-mediated tumor protection. J. Mol. Med. (Berl.) 2014, 92:1283-1292.
115. Sitkovsky M.V., Hatfield S., Abbott R., Belikoff B., Lukashev D., Ohta A. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol. Res. 2014, 2:598-605.
116. Beavis P.A., Divisekera U., Paget C., Chow M.T., John L.B., Devaud C., et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:14711-14716.
117. Beavis P.A., Milenkovski N., Henderson M.A., John L.B., Allard B., Loi S., et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol. Res. 2015, 3:506-517.
118. Leone R.D., Lo Y.C., Powell J.D. A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput. Struct. Biotechnol. J. 2015, 13:265-272.
119. Iannone R., Miele L., Maiolino P., Pinto A., Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am. J. Cancer Res. 2014, 4:172-181.
120. Stagg J., Divisekera U., McLaughlin N., Sharkey J., Pommey S., Denoyer D., et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1547-1552.
121. Jin D., Fan J., Wang L., Thompson L.F., Liu A., Daniel B.J., et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010, 70:2245-2255.
122. Daniel-Meshulam I., Horovitz-Fried M., Cohen C.J. Enhanced antitumor activity mediated by human 4-1BB-engineered T cells. Int. J. Cancer 2013, 133:2903-2913.
123. Stephan M.T., Ponomarev V., Brentjens R.J., Chang A.H., Dobrenkov K.V., Heller G., et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 2007, 13:1440-1449.
124. Teijeira A., Palazon A., Garasa S., Marre D., Auba C., Rogel A., et al. CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells. FASEB J. 2012, 26:3380-3392.
125. Bartkowiak T., Curran M.A. 4-1BB agonists: multi-potent potentiators of tumor immunity. Front. Oncol. 2015, 5:117.
126. Weigelin B., Bolanos E., Teijeira A., Martinez-Forero I., Labiano S., Azpilikueta A., et al. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:7551-7556.
127. Sun J., Dotti G., Huye L.E., Foster A.E., Savoldo B., Gramatges M.M., et al. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol. Ther. 2010, 18:2006-2017.
128. Riese M.J., Wang L.C., Moon E.K., Joshi R.P., Ranganathan A., June C.H., et al. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res. 2013, 73:3566-3577.
129. Hinterleitner R., Gruber T., Pfeifhofer-Obermair C., Lutz-Nicoladoni C., Tzankov A., Schuster M., et al. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PLoS ONE 2012, 7:e44295.
130. Wu Y., Deng Z., Tang Y., Zhang S., Zhang Y.Q. Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity. BMC Cancer 2015, 15:603.
131. Buferne M., Chasson L., Grange M., Mas A., Arnoux F., Bertuzzi M., et al. IFNgamma producing CD8 T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. Oncoimmunology 2015, 4:e974959.
132. Ji Y., Wrzesinski C., Yu Z., Hu J., Gautam S., Hawk N.V., et al. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic gammac cytokines. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:476-481.
133. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006, 6:595-601.
134. Zhou P., Shaffer D.R., Alvarez Arias D.A., Nakazaki Y., Pos W., Torres A.J., et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 2014, 506:52-57.
135. Giordano M., Roncagalli R., Bourdely P., Chasson L., Buferne M., Yamasaki S., et al. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:11115-11120.
136. Li C., Li W., Xiao J., Jiao S., Teng F., Xue S., et al. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol. Med. 2015, 7:754-769.
137. Dotti G., Savoldo B., Pule M., Straathof K.C., Biagi E., Yvon E., et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005, 105:4677-4684.
138. Kalbasi A., Shrimali R.K., Chinnasamy D., Rosenberg S.A. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J. Immunother. 2010, 33:672-683.
139. Di Stasi A., Tey S.K., Dotti G., Fujita Y., Kennedy-Nasser A., Martinez C., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365:1673-1683.
140. Flavell R.A., Sanjabi S., Wrzesinski S.H., Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 2010, 10:554-567.
141. Chou C.K., Schietinger A., Liggitt H.D., Tan X., Funk S., Freeman G.J., et al. Cell-intrinsic abrogation of TGF-beta signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J. Immunol. 2012, 189:3936-3946.
142. Quatromoni J.G., Wang Y., Vo D.D., Morris L.F., Jazirehi A.R., McBride W., et al. T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFbeta) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J. Transl. Med. 2012, 10:127.
143. Bollard C.M., Rossig C., Calonge M.J., Huls M.H., Wagner H.J., Massague J., et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002, 99:3179-3187.
144. Bendle G.M., Linnemann C., Bies L., Song J.Y., Schumacher T.N. Blockade of TGF-beta signaling greatly enhances the efficacy of TCR gene therapy of cancer. J. Immunol. 2013, 191:3232-3239.
145. Yang B., Liu H., Shi W., Wang Z., Sun S., Zhang G., et al. Blocking transforming growth factor-beta signaling pathway augments antitumor effect of adoptive NK-92 cell therapy. Int. Immunopharmacol. 2013, 17:198-204.
146. Zhao Y., Hu J., Li R., Song J., Kang Y., Liu S., et al. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-beta signaling pathway. Onco Targets Ther. 2015, 8:1553-1559.
147. Wallace A., Kapoor V., Sun J., Mrass P., Weninger W., Heitjan D.F., et al. Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res. 2008, 14:3966-3974.
148. Zurkova K., Chlanda P., Samkova Z., Babiarova K., Kutinova L., Krystofova J., et al. Expression of soluble TGF-beta receptor II by recombinant Vaccinia virus enhances E7 specific immunotherapy of HPV16 tumors. Neoplasma 2011, 58:181-188.
149. Sato T., Terai M., Tamura Y., Alexeev V., Mastrangelo M.J., Selvan S.R. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol. Res. 2011, 51:170-182.
150. Terai M., Tamura Y., Alexeev V., Ohtsuka E., Berd D., Mastrangelo M.J., et al. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol. Immunother. 2009, 58:1307-1317.
151. Ahn Y.H., Hong S.O., Kim J.H., Noh K.H., Song K.H., Lee Y.H., et al. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-beta receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. Clin. Exp. Immunol. 2015, 181:164-178.
152. Wang L.X., Westwood J.A., Moeller M., Duong C.P., Wei W.Z., Malaterre J., et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res. 2010, 70:9591-9598.
153. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346-2357.
154. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 1993, 178:1223-1230.
155. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997, 90:2541-2548.
156. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 1989, 210:474-484. discussion 484-475.
157. Zhang L., Kerkar S.P., Yu Z., Zheng Z., Yang S., Restifo N.P., et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 2011, 19:751-759.
158. Pegram H.J., Purdon T.J., van Leeuwen D.G., Curran K.J., Giralt S.A., Barker J.N., et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 2014, 29:415-422.
159. Chmielewski M., Kopecky C., Hombach A.A., Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011, 71:5697-5706.
160. Koneru M., Purdon T.J., Spriggs D., Koneru S., Brentjens R.J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors. Oncoimmunology 2015, 4:e994446.
161. Koneru M., O'Cearbhaill R., Pendharkar S., Spriggs D.R., Brentjens R.J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 2015, 13:102.
162. Chmielewski M., Abken H. TRUCKs: the fourth generation of CARs. Expert Opin. Biol. Ther. 2015, 15:1145-1154.
163. Hoyos V., Savoldo B., Quintarelli C., Mahendravada A., Zhang M., Vera J., et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24:1160-1170.
164. Klebanoff C.A., Gattinoni L., Torabi-Parizi P., Kerstann K., Cardones A.R., Finkelstein S.E., et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9571-9576.
165. Berger C., Jensen M.C., Lansdorp P.M., Gough M., Elliott C., Riddell S.R. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 2008, 118:294-305.
166. Xu Y., Zhang M., Ramos C.A., Durett A., Liu E., Dakhova O., et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 2014, 123:3750-3759.
167. Wu A.A., Drake V., Huang H.S., Chiu S., Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 2015, 4:e1016700.
168. Leen A.M., Sukumaran S., Watanabe N., Mohammed S., Keirnan J., Yanagisawa R., et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 2014, 22:1211-1220.
169. Feldman S.A., Assadipour Y., Kriley I., Goff S.L., Rosenberg S.A. Adoptive cell therapy-tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors. Semin. Oncol. 2015, 42:626-639.
170. Besser M.J., Shapira-Frommer R., Itzhaki O., Treves A.J., Zippel D.B., Levy D., et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 2013, 19:4792-4800.
171. Barrett D.M., Grupp S.A., June C.H. Chimeric Antigen Receptor- and TCR-Modified T cells enter main street and wall street. J. Immunol. 2015, 195:755-761.
172. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29:917-924.
173. Duval L., Schmidt H., Kaltoft K., Fode K., Jensen J.J., Sorensen S.M., et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin. Cancer Res. 2006, 12:1229-1236.
174. Burns W.R., Zheng Z., Rosenberg S.A., Morgan R.A. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 2009, 114:2888-2899.
175. Maude S.L., Barrett D., Teachey D.T., Grupp S.A. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014, 20:119-122.
176. Hacohen N., Fritsch E.F., Carter T.A., Lander E.S., Wu C.J. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol. Res. 2013, 1:11-15.
177. Garrett W.S. Cancer and the microbiota. Science 2015, 348:80-86.
178. Adusumilli P.S., Cherkassky L., Villena-Vargas J., Colovos C., Servais E., Plotkin J., et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 2014, 6. 261ra151.
179. Moeller M., Haynes N.M., Kershaw M.H., Jackson J.T., Teng M.W., Street S.E., et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood 2005, 106:2995-3003.
180. Sommermeyer D., Hudecek M., Kosasih P.L., Gogishvili T., Maloney D.G., Turtle C.J., et al. Chimeric antigen receptor-modified T cells derived from defined CD8 and CD4 subsets confer superior antitumor reactivity in vivo. Leukemia 2015, 10.1038/leu.2015.247.
181. Benson D.M., Caligiuri M.A. Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol. Res. 2014, 2:99-104.
182. Miller J.S. Therapeutic applications: natural killer cells in the clinic. Hematol. Am. Soc. Hematol. Educ. Program 2013, 2013:247-253.
183. Bachanova V., Miller J.S. NK cells in therapy of cancer. Crit. Rev. Oncog. 2014, 19:133-141.
184. Heczey A., Liu D., Tian G., Courtney A.N., Wei J., Marinova E., et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 2014, 124:2824-2833.
185. Deniger D.C., Switzer K., Mi T., Maiti S., Hurton L., Singh H., et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol. Ther. 2013, 21:638-647.